Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out how effective the combination of crizotinib and
fulvestrant is in shrinking lobular breast cancer tumours. The investigators will also be
assessing the side effects of the combination of crizotinib tablets and fulvestrant
injections. The side effects and the doses of crizotinib and fulvestrant have already been
evaluated in large clinical trials, but this is the first time these two drugs will be
combined together.